RT Journal Article
SR Electronic
T1 Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen Test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.08.21250086
DO 10.1101/2021.02.08.21250086
A1 Koskinen, Juha M.
A1 Antikainen, Petri
A1 Hotakainen, Kristina
A1 Haveri, Anu
A1 Ikonen, Niina
A1 Savolainen-Kopra, Carita
A1 Koskinen, Janne O.
YR 2021
UL http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250086.abstract
AB Novel SARS coronavirus causing COVID-19 was recognized in late 2019. Diagnostics was quickly ramped up worldwide based on the detection of viral RNA. Based on the scientific knowledge for pre-existing coronaviruses, it was expected that the RNA of this novel coronavirus will be detected at significant rates from symptomatic and asymptomatic individuals due to existence of non-infectious RNA. To increase the efficacy of diagnostics, surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed for decentralized testing and to assess infectiousness. The objectives were to verify analytical sensitivity and specificity, and assess the clinical sensitivity, specificity and usability of a novel automated mariPOC SARS-CoV-2 test based on sophisticated optical laser technology detecting viral structure proteins. Analytical performance was verified using bacterial and viral preparations. Clinical performance of the test was evaluated against qRT-PCR in a retrospective study with nasopharyngeal swab specimens (N=211) collected from symptomatic patients suspected of acute SARS-CoV-2 infections. Sensitivity and specificity of the mariPOC test were 92.3% (12/13) and 100.0% (198/198), respectively. The test’s limit of detection was 22 PFU/test and it had no cross-reactions with the tested respiratory microbes. Our study shows that the mariPOC can detect infectious individuals already in 20 minutes while clinical sensitivity close to qRT-PCR is achieved in two hours or less. The test targets conserved epitopes of SARS-CoV-2 nucleoprotein, making it robust against strain variations. The new test is a promising and versatile tool for syndromic testing of symptomatic cases and for high capacity infection control screening.Competing Interest StatementJMK, PA and JOK are employees at ArcDia International Ltd.Funding StatementArcDia International Ltd contributed the study with the mariPOC test system and consumables. The study was partly supported by Business Finland, the Finnish Funding Agency for Innovation, under the project reference 35239/31/2020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was approved by the responsible Chief Medical Officer physician of Mehiläinen Oy, Dr., docent Kaisla Lahdensuo.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised line data is available upon request.